Gemtuzumab ozogamicin

Iz Wikipedije, slobodne enciklopedije
Gemtuzumab ozogamicin
Klinički podaci
Robne marke Mylotarg, Mylotarg (Wyeth)
AHFS/Drugs.com ozogamicin.html Monografija
Identifikatori
CAS broj 220578-59-6
ATC kod L01XC05
DrugBank DB00056
ChEMBL[1] CHEMBL1201506 YesY
Hemijski podaci
Formula  ?
Mol. masa 0,000
Fizički podaci
Tačka topljenja 61 °C (142 °F)
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status
Način primene Intravenozno

Gemtuzumab ozogamicin (Mylotarg) je lek vezan za monoklonalno antitelo koji je korišten za tretiranje akutne mijelocitne leukemije tokom perioda 2000-2010. On je povučen sa tržišta u junu 2010, kad su klinička ispitivanja pokazala da povećava stopu smrtnosti pacijenata i da nema prednosti od njegove primene u odnosu na konvencionalne terapije kancera.[2][3][4][5][6]

Reference[uredi - уреди | uredi izvor]

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. PMID 11410481
  3. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. PMID 11466696
  4. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 1;102(5):1578-82. Epub 2003 May 8. PMID 12738663
  5. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126.  edit
  6. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958.  edit

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).